Endovascular Engineering (E2) announced today that it raised $80 million in an oversubscribed Series C financing round.
Medical Device Network on MSN
E2 raises $80m to advance VTE system’s commercialisation
FDA-cleared in December 2025, E2’s Hēlo system is indicated for the non-surgical removal of emboli and thrombi from pulmonary ...
E2 raises $80M to scale Hēlo®, improving pulmonary embolism treatment with faster, safer, and more efficient procedures.
Endovascular Engineering, Inc. ("E2"), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), today announced an oversubscribed $80 million ...
The funding round follows high-profile acquisitions by Boston Scientific and Stryker to pick up mechanical thrombectomy ...
California-based medtech E2 (Endovascular Engineering) has raised $80 million in a series C funding round as it looks to commercialize its pulmonary embolism treatment. | California-based medtech E2 ...
Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on the treatment of venous thromboembol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results